What is Bextra?

Bextra (Valdecoxib) is similar to Celebrex (Celecoxib) in the respect that it is a prescription COX-2 selective inhibitor nonsteroidal anti-inflammatory drug (NSAID) used for the relief of pain associated with osteoarthritis (OA), rheumatoid arthritis (RA) and menstrual cramps (primary dysmenorrhea). Bextra was manufactured by Pharmacia Corporation/Pfizer, Inc., and it was approved for these purposes by the Food and Drug Administration (FDA) on November 16, 2001. The marketing of Bextra started in March 2002.

Bextra, similar to Celebrex, works by inhibiting the COX-2 form of the COX enzyme to block production of prostaglandins. Prostaglandins are hormone-like substances that contribute to the symptoms of pain, fever and inflammation.

Bextra tablets for oral administration contain either 10 mg or 20 mg of the active ingredient, valdecoxib. Inactive ingredients include lactose monohydrate, microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, magnesium stearate, hydroxypropyl methylcellulose, polyethylene glycol, polysorbate 80, and titanium dioxide.

The information on this page is meant to provide a general overview of the law. The laws in your state and/or city may deviate significantly from those described here. If you have specific questions related to your situation you should speak with a local attorney.

Additional Bextra Articles

Search LawInfo's Bextra Resources

Related Topics In This Section